Molecular genetics of acute leukaemia

Lancet

Volumn 349, Issue 9046, 1997, Pages 196-200

  Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE; RETINOIC ACID; RETINOIC ACID RECEPTOR;

CANCER; CHROMOSOME TRANSLOCATION; HUMAN; LEUKEMIA; MOLECULAR GENETICS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0031033477     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)07535-6     Document Type: Review

References (40)

1. Zeleznik-Le NJ, Nucifora G, Rowley JD. The molecular biology of myeloproliferative disorders as revealed by chromosomal abnormalities. Sem Hematol 1995; 32: 201-19.
2. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372: 143-49.
3. Chen SJ, Wang ZY, Chen Z. Acute promyelocytic leukemia: from clinic to molecular biology. Stem Cells 1995; 13: 22-31.
4. Rubnitz JE, Behm FG, Downing JR. 11q23 rearrangements in acute leukemia. Leukemia 1991; 10: 78-82.
5. Erickson P, Gao J, Chang K-S, et al. Identification of breakpoints in t(8; 21) AML and isolation of a fusion transcript with similarity to Drosophila segmentation gene runt. Blood 1992; 80: 1825-31.
6. Miyoshi H, Shimizu K, Kozu T, et al. The t(8; 21) breakpoints in chromosome 21 in acute myeloid leukemia clustered within a limited region of a novel gene, AML1. Proc Natl Acad Sci USA 1993; 88: 10431-35.
7. Nucifora G, Begy CR, Erickson P, Drabkin HA, Rowly JD. The 3; 21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1. Proc Natl Acad Sci USA 1993; 90: 7784-88.
8. Mitani K, Ogawa S, Tanaka T, et al. Generation of AML1/EVI1 fusion gene in the t(3; 21) (q26; q22) causes blastic crisis in chronic myelocytic leukemia. Embo J 1994; 13: 504-10.
9. Golub TR, Barker GF, Bohlander SK, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995; 92: 4917-921.
10. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84: 321-30.
11. Nucifora G, Begy CR, Kobayashi H, et al. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3; 21) (q26; q22) translocations. Proc Natl Acad Sci USA 1994; 91: 4004-08.
12. Matsugi T, Morishita K, Ihle JN. Identification, nuclear localization, and DNA-binding activity of the zinc finger protein encoded by the Evi-1 myeloid transforming gene. Mol Cell Biol 1990; 10: 1259-64.
13. Erickson PF, Robinson M, Owens G, Drabkin HA. The ETO portion of acute myeloid leukemia t(8; 21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor. Cancer Res 1994; 54: 1782-86.
14. Meyers S, Lenny N, Hiebert SW. The t(8; 21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 1995; 15: 1974-82.
15. Zent CS, Mathieu C, Claxton DF, et al. CSF1R promoter, but only AML1/MDS1 has tumour-promoter properties. Proc Natl Acad Sci USA 1996; 93: 1044-48.
16. Romana SP, Poirel H, Leconiat M, et al. High frequency of t(12; 21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995; 86: 4263-69.
17. Liu P, Tarle SA, Hajra A, et al. Fusion between transcription factor CBFβ/PEBP2β and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261: 1041-44.
18. Hajra A, Liu PP, Wang Q, et al. The leukemic core binding factor b-smooth muscle myosin heavy chain (CBFb-SMMHC) chimeric protein requires both CBFb and myosin heavy chain domains for transformation of NIH 3T3 cells. Proc Natl Acad Sci USA 1995; 92: 1926-30.
19. Hajra A, Liu PP, Collins FS. Transforming properties of the leukemic inv(16) fusion gene CBFB-MYH11. Curr Top Microb Immun 1996; 211: 289-98.
20. Wang Q, Stacy T, Miller JD, et al. The CBFβ subunit is essential for CBFα2 (AML1) function in vivo. Cell 1996; 87: 697-708.
21. Kurokawa M, Ogawa S, Tanaka T, et al. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence. Oncogenes 1995; 11: 833-40.
22. Castilla LH, Wijmenga C, Wang Q, et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous from a knocked-in leukaemia gene CBFβMYH 11. Cell 1996; 87: 687-96.
23. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome positive leukemias. N Engl J Med 1988; 319: 990-98.
24. Witte ON, Dasgupta A, Baltimore D. Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature 1980; 283: 826-31.
25. Laneuville P. Abl tyrosine protein kinase. Sem Immunol 1995; 74: 255-66.
26. Prendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175-85.
27. Senechal K, Halpern J, Sawyers CL. The CRKL adaptor protein transforms fibroblasts and functions in transformation by the Bcr-Abl oncogene. J Biol Chem 1996; 271: 23255-61.
28. Schlessinger J. SH2/SH3 signaling proteins. Curr Opin Genet Dev 1994; 4: 25-30.
29. Ihle JN, Kerr IM. Jaks and stats in signaling by the cytokine receptor superfamily. Trends Genet 1995; 11: 69-74.
30. Gishizky ML, Witte ON. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 1992; 256: 836-39.
31. Shuai K, Halpern J, Hoeve J, Rao X, Sawyers CL. Constitutive activation of STATS by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996; 13: 247-54.
32. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by BCR/ABL. J Exp Med 1996; 183: 811-20.
33. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5; 12) chromosomal translocation. Cell 1994; 77: 307-16.
34. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiederman LM. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 1995; 55: 34-38.
35. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nuclear protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-84.
36. McWhirter JR, Galasso DL, Wang YL. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 1993; 13: 7587-95.
37. Golub TR, Goga A, Barker G, et al. Oligomerization of the ABL tyrosine kinase by the ETS protein TEL in human leukemia. Mol Cell Biol 1996; 16: H107-16.
38. Kaur G, Gazit A, Levitski A, Stowe E, Cooney D A, Sausville EA. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anti-Cancer Drugs 1994; 5: 213-22.
39. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994; 77: 175-78.
40. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-66